0.15Open0.15Pre Close0 Volume23 Open Interest0.50Strike Price0.00Turnover219.38%IV-6.07%PremiumAug 16, 2024Expiry Date0.19Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8068Delta0.7042Gamma2.77Leverage Ratio-0.0023Theta0.0002Rho2.23Eff Leverage0.0005Vega
Gritstone Bio Stock Discussion
NEWS
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024
NEWS
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE --
-- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. ...
No comment yet